Merck & Co. To Release Findings From Integrated Analysis Of Six Phase 2 And 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir In Patients With Chronic Hepatitis C Genotype 1, 4 Or 6 Infection And Compensated Cirrhosis At The Liver Meeting

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection.

Help employers find you! Check out all the jobs and post your resume.